DHG decides not to invest in Myanmar drug factory
In July, DHG had planned to acquire a 72.86 per cent stake in ASV Pharma Viet Nam, a move that was meant to allow DHG to indirectly hold a 51 per cent stake in ASV Pharma Myanmar and enter the Myanmar market.
It was expected that the new drug factory in Myanmar would promote drug exports and bring revenues for DHG.
A representative from Hau Giang Pharma told the Doi Song Phap Luat (Life and Laws news online) that regardless of the withdrawal of investment, DHG will continue to do market research to expand its distribution network in Myanmar.
As many as 17 registered pharmaceutical products of DHG are in circulation in Myanmar, and five more products are scheduled to be introduced in the market by 2015.
By the end of August, DHG had gained VND2,315 billion (US$110 million) in net sales, an increase of 15.4 per cent year on year.
What the stars mean:
★ Poor ★ ★ Promising ★★★ Good ★★★★ Very good ★★★★★ Exceptional
Latest News
More News
- Interest must rise for carbon exchange (December 19, 2024 | 16:00)
- Limitations abound for domestic EV carbon credits (December 19, 2024 | 15:00)
- Businesses pivotal in offsetting carbon measures in Vietnam (December 19, 2024 | 13:00)
- Coordination key for circular economy (December 19, 2024 | 10:56)
- Vietnam’s first logistics laboratory established (December 19, 2024 | 08:00)
- Masan Consumer Holdings honoured with consecutive "Great Place To Work" certifications (December 18, 2024 | 16:55)
- SABECO’s research facility a dream for its brewmasters (December 17, 2024 | 10:30)
- Digital twins reshaping Vietnam's logistics and supply chain landscape (December 17, 2024 | 09:34)
- Enterprises awarded for pioneering innovation to attract talent (December 16, 2024 | 16:43)
- Testing future predicted for technology startups in Vietnam (December 14, 2024 | 15:00)
Mobile Version